Oxford Biomedica PLC

Director's Dealing • Dec 8, 2025

National Storage Mechanism | Additional information

RNS Number : 7024K

Oxford Biomedica PLC

08 December 2025

PDMR Dealing

Oxford, UK - 08 December 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Lisa Doman, Chief People Officer and Kyriacos Mitrophanous, Chief Innovation Officer have exercised their respective 3,057 SAYE 2022 options at an exercise price of £2.944 on 08 December 2025 and disposed of their respective 3,057 shares at an average price of £6.23026 per share on 08 December 2025.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lisa Doman

2.

Reason for the notification

a)

Position/status

Person Discharging Managerial Responsibility

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Full name of the entity

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

2025-12-08

b)

Description of the financial instrument

SAYE Options over Ordinary Shares of 50 pence each

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of the transaction

Exercise of SAYE 2022 Options at £2.944

e)

Place of the transaction

Outside the trading venue

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
£2.944	3,057

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

3,057

£2.944

£8999.81

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lisa Doman

2.

Reason for the notification

a)

Position/status

Person Discharging Managerial Responsibility

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

2025-12-08

b)

Description of the financial instrument

Ordinary Shares of 50 pence each

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of transaction

Sale of shares

e)

Place of the transaction

London Stock Exchange, Main Market (XLON)

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
£6.23026	3,057

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

3,057

£6.23026

£19,045.90

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Person Discharging Managerial Responsibility

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Full name of the entity

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

2025-12-08

b)

Description of the financial instrument

SAYE Options over Ordinary Shares of 50 pence each

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of the transaction

Exercise of SAYE 2022 Options at £2.944 exercise price

e)

Place of the transaction

Outside of the trading venue

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
£2.944	3,057

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

3,057

£2.944

£8999.81

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Person Discharging Managerial Responsibility

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

2025-12-08

b)

Description of the financial instrument

Ordinary Shares of 50 pence each

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of transaction

Sale of shares

e)

Place of the transaction

London Stock Exchange, Main Market (XLON)

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
£6.23026	3,057

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

3,057

£6.23026

£19,045.90

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: [email protected]

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPKFBDPBDDKBK